Axis Bank stock post Q1 results? Buy, Sell or Hold?

Net interest income (NII) grew by 19.5 percent year-on-year to Rs 6,985.3 crore in the quarter.

Axis Bank share price rose 8 percent in the early trade on July 22 after the company reported its first quarter earnings.

The company has reported an 18.8 percent year-on-year decline in standalone profit for the June quarter to Rs 1,112.17 crore compared to Rs 1,370.08 crore in the corresponding period last year.

Net interest income (NII) grew by 19.5 percent year-on-year to Rs 6,985.3 crore in the quarter, with strong loan growth of 17 percent (including TLTRO investments) and deposits growth of 19 percent on a quarterly average basis (QAB).

The private lender's savings account deposits grew 15 percent YoY, current account deposits 8 percent and retail term deposits (RTD) were up 27 percent on QAB basis while including TLTRO (Targeted Long Term Repo Operations) investments, corporate loans grew 26 percent and retail loans 16 percent.

Here's what brokerages are saying about the stock and the company:

Credit Suisse | Rating: Outperform | Target: Raises to Rs 550 from Rs 450

CLSA | Rating: Buy | Target: Raised to Rs 600 from Rs 580

Jefferies | Rating: Buy | Target: Raised to Rs 550 from Rs 530

Prabhudas Lilladher | Rating: Hold | Target: Rs 480

Motilal Oswal | Rating: Buy | Target: Rs 600

Source - Moneycontrol

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog